Latest COX-2 inhibitor Stories

MISSISSAUGA, ON, March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV), has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully...

GREENWOOD VILLAGE, Colo., Feb. 25, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced today that it's Phase III clinical study of Ampion(TM) for the treatment for osteoarthritis of the knee will include a dose-escalation run-in( )study as recommended by the FDA. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, explained "In the Australian trial, a single 4 ml dose provided promising...

Diclofenac most commonly used non-steroidal anti-inflammatory drug in 15 countries, listed on 74 national drug lists, despite cardiovascular risks A study in this week's PLOS Medicine finds that the painkiller diclofenac (a non-steroidal anti-inflammatory drug (NSAID) in the same class as aspirin) is the most commonly used NSAID in the 15 countries studied and is included in the essential medicines lists of 74 low-, middle- and high-income countries, despite its known tendency to cause...

FRANKFURT, Germany and LONDON, February 4, 2013 /PRNewswire/ -- The Federal Association of German Pharmacists (BVDA) today presented its "Innovation Award 2013" to FLEXISEQ(R), an innovative new treatment for pain and stiffness associated with osteoarthritis (OA). The BVDA president, and pharmacist Thomas Hieble, explained; "The jury awarded the prize to FLEXISEQ(R) in recognition of the application of its innovative Sequessome Technology(R) to deliver symptom relief to...

MISSISSAUGA, ON, Jan. 29, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX: NRI) announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a...

PHILADELPHIA, Dec. 12, 2012 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia's Navy Yard Corporate Center. This milestone is part of the Company's long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal...

EUGENE, Ore., Dec. 5, 2012 /PRNewswire/ -- The American Heart Association (AHA) has become a member of the Alliance for the Rational Use of NSAIDs, joining a growing list of patient and provider organizations committed to supporting the safe and appropriate use of nonsteroidal anti-inflammatory drugs (NSAIDs).The announcement comes after the September release of new research in AHA journal Circulation, which found that heart attack survivors who take NSAIDs face a significantly...

Nearly a quarter of patients with rheumatoid arthritis and osteoarthritis used complementary and alternative therapy (CAT) to help manage their condition, according to a study in the November issue of the Journal of Clinical Nursing. Researchers interviewed 250 patients aged between 20 and 90 years of age. More than two-thirds (67%) had rheumatoid arthritis and the remainder had osteoarthritis. They found that 23% used CAT in addition to prescribed drugs and that just under two-thirds...

MISSISSAUGA, ON, Sept. 5, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that the United States Patent Office has issued United States Patent # 8,252,838 relating to compositions and methods of using PENNSAID(®) (diclofenac sodium topical solution) 2.0% w/w (PENNSAID 2% Patent).  The patent expires on April 21, 2028. Nuvo's U.S. licensing...

MENLO PARK, Calif., June 21, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has acquired all rights to Zipsor(®) (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. The product uses proprietary ProSorb(®) delivery technology to deliver a finely dispersed, rapidly absorbed formulation of diclofenac....